CDK to Offer Dealers a More Open and Inclusive DMS Platform
Today, CDK Global’s International business revealed plans for an evolution of its dealer management platform that will enable automotive retailers to manage the customer journey from online to offline more efficiently and profitably. Building on CDK’s market-leading position, a new programme of openness in platform development will allow selected third-party applications to integrate with CDK’s core dealer management platform and better enable end-to-end automotive commerce.
The new move coincides with the launch of a rapid product development programme, which will enable CDK to deliver new innovations to global markets. This approach will see CDK research and development teams work more closely with retailers, partners and consumers to identify issues, explore new efficiencies and develop new products and services. Examples of recent innovations include integration between CitNow, a video capture product to increase transparency and trust in the aftersales process and the DMS, but also new products such as SmartPay in Demark, a mobile payment solution for service departments.
Neil Packham, President of CDK International, said: “The world has moved on from all customer interaction being inside a dealership. Now the digital journey plays a major role, so customer interactions can occur anywhere, at any time – often in a virtual space. We already use vehicle manufacturer interfaces to provide a more joined-up customer experience and save many work hours for dealership staff. Now, we are developing new innovations and partnerships that will complement and evolve existing products, enabling retailers to be even more efficient, effective, and profitable.”
Through its existing partnership programmes with manufacturers, CDK has already developed and released a proven suite of interfaces that allow access to multiple-systems and network-wide information within its integrated Autoline Drive DMS software.
The two-way sharing of vehicle and other data between retailers and vehicle manufacturers is an industry-first that has the potential to free-up thousands of hours for dealership staff and improve the customer experience. For example, a short code can be generated from a selected manufacturer’s online car configurator, using factory build data for exact specifications, which can then be used in dealership processes and throughout the ownership cycle.
Now, as part of CDK’s product evolution programme, retailers will have the option of integrating partner applications with the core DMS platform. Whether it is a vehicle manufacturer-mandated showroom system, dedicated CRM software or a marketing tool, CDK’s new approach will enable selected systems to integrate with the DMS platform and communicate with each other.
CDK Global invests heavily in research and development, identifying the challenges faced by automotive retailers all over the world to help develop new technologies that keep dealerships up to date with changing consumer preferences. As a technology partner for vehicle manufacturers and dealer networks, CDK helps transform retailers by enabling total integration of DMS with dealership operations, delivering innovative management and analysis tools to allow easy adoption of emerging technologies in automotive retail.
Notes to editors
About CDK Global
With more than $2 billion in revenues, CDK Global (Nasdaq:CDK) is a leading global provider of integrated information technology and digital marketing solutions to the automotive retail and adjacent industries. Focused on evolving the automotive retail experience, CDK Global provides solutions to dealers in more than 100 countries around the world, serving approximately 28,000 retail locations and most automotive manufacturers. CDK's solutions automate and integrate all parts of the dealership and buying process from targeted digital advertising and marketing campaigns to the sale, financing, insuring, parts supply, repair and maintenance of vehicles.
For more information about CDK in the UK, visit www.cdkglobal.co.uk
For further information, images or comment, please contact PFPR
T: +44 (0)1622 766521
M : +44 (0)7515 060527
T: +44 (0)1622 776681
M: +44 (0)7715 075992
T: +44 (0)1622 776680
M: +44 (0)7816 906794
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Synteract Announces Collaboration with International Children’s Advisory Network iCAN Research25.6.2018 20:03 | Tiedote
Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event. With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide. In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will sup
GA-ASI to Fly First Trans-Atlantic Flight of a MALE RPA25.6.2018 19:55 | Tiedote
On July 10-11, General Atomics Aeronautical Systems, Inc. (GA-ASI) plans to make the first-ever trans-Atlantic flight of a Medium-altitude, Long-endurance (MALE) Remotely Piloted Aircraft (RPA). GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static display July 13-15 for the Royal International Air Tattoo (RIAT) airshow being held at RAF Fairford. The flight and display will commemorate the RAF’s centenary celebration (RAF100). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005946/en/ GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static displa
Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30 | Tiedote
www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re
The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00 | Tiedote
The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and
Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22 | Tiedote
Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07 | Tiedote
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme